Wedbush analyst Laura Chico lowered the firm’s price target on Ultragenyx to $47 from $49 and keeps a Neutral rating on the shares. Ultragenyx reported Q2 results that were largely as anticipated and management reiterated all elements of FY23 financial guidance, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
- Ultragenyx sees FY23 revenue $425M-$450M, consensus $437.55M
- Ultragenyx reports Q2 EPS ($2.25), consensus ($2.07)
- 3 Best Stocks to Buy Now, 8/2/2023, According to Top Analysts
- Ultragenyx initiates dosing in second cohort of Phase 1/2/3 Cyprus2+ study